DEVELOPMENT OF BIOMARKER FOR KETOGENIC DIET–BASED CANCER TREATMENT

摘要

Provided are a method for selecting cancer patients for which ketogenic diet therapy would be effective, and a method for predicting the effectiveness of ketogenic diet therapy on cancer patients. The selection method is characterized by obtaining, from blood serum derived from a cancer patient prior to ingesting a ketogenic diet, analysis results for at least one pre-ingestion candidate substance selected from the group consisting of acylcarnitine(12:0), acylcarnitine(12:1)-2, acylcarnitine(12:1)-3, acylcarnitine(14:1)-1, acylcarnitine(14:2)-1, acylcarnitine(14:2)-2, acylcarnitine(14:3)-2, acylcarnitine(16:1), acylcarnitine(16:2), anandamide, heptadecenoic acid, hypotaurine, linoleoylethanolamide, palmitoleic acid, palmitoylcarnitine, phytosphingosine, quinic acid, uric acid, alanine, citrulline, tryptophan, and lysine, and using the analysis results as an indicator.